Talquetamab 是种人源化的双特异性抗体，可与 GPRC5D和 CD3 结合，通过T细胞的募集和活化诱导T细胞介导的杀死表达GPRC5的MM细胞 | MedChemExpress (MCE)

Talquetamab

CAS：2226212-40-2

品牌：MedChemExpress (MCE)

存储条件：Please store the product under the recommended conditions in the Certificate of Analysis.

生物活性：Talquetamab（JNJ-64407564）是一种人源化的双特异性抗体，可与 GPRC5D (G 蛋白偶联受体家族C5组成员 D) 和 CD3 结合，通过T 细胞的募集和活化诱导 T 细胞介导的杀死表达 GPRC5 的 MM 细胞。Talquetamab（JNJ-64407564）具有抗肿瘤活性。

体外：Talquetamab (0.00128-4.0 μg/mL, 48 h) 有效诱导多发性骨髓瘤细胞裂解，并导致活化的 CD4+ 和CD8+ T 细胞比例显著增加，以及颗粒酶 B 和炎症细胞因子如 IL-6、IL-8 和 TNF-α 水平的剂量依赖性增加[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内：Talquetamab (JNJ-64407564) (0.1-50 µg, s.c. or i.v.)在 H929 和 MM 小鼠模型中有明显的抗肿瘤活性[2]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female NSG mice with H929 cells[2] Dosage: 0.1-10 µg (0.005 mg/kg) Administration: Subcutaneous injection; on days 0, 3, 5, 7, and 10 Result: Completely blocked tumor formation at 1 μg and 10 μg doses. Animal Model: Female NSG mice with human MM cells[2] Dosage: 0.1-50 µg (0.005 mg/kg) Administration: Intravenous injection; on days 15, 18, 22, 24, 29, 32, and 36 Result: Significantly inhibited tumor growth by 65% at the dose of 1μg and showed significant anti-tumor activity at 10 and 50 μg with complete tumor regression. Clinical Trial

参考文献：

[1]. Christie P M Verkleij, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 2021 Apr 27;5(8):2196-2215.
[2]. Kodandaram Pillarisetti, et al. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood. 2020 Apr 9;135(15):1232-1243.